In the News... Tzield approved for newly diagnosed T1D, GLP-1 studies for type 1, ADA 2026 highlights and more!
Episode Description
It's In The News - a look at the top diabetes stories and headlines happening now!
Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com
Episode transcript:
fall Detroit and Seattle.
Okay.. our top story this week:
XX
The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D.
XX
Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.
The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications.
You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA.
XX
New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use.
Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%.
The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia.
XX
A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes.
The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure.
https://www.medpagetoday.com/meetingcoverage/ada/121658
XX
Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin.
The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me
https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children
XX
Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes.
The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity
Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.
XX
Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe.
More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this.
--
Back to the news..
XX
Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more.
XX
Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks
XX
Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.
--
MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year.
XX
Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes.
XX
Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard.
XX
MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval.
XX
Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.
XX
Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor.
XX
Long-time T1D advocate Kent Schnakenberg died last week.
Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money.
According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days.
https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/
https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/
XX
And finally.
Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic.
"Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want."
He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries."
https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition
Listen On
